CRVS Corvus Pharmaceuticals, Inc.

NASDAQ
$10.54

Corvus Pharmaceuticals, Inc. (CRVS) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is a loss of $0.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.0% since its last earnings release on November 5, 2026.

Corvus Pharmaceuticals Missed Consensus Estimates
Thursday, November 5, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($0.21)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $10.54

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidate is mupadolimab (CPI-006), a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.